Perioperative Evaluation of Glucose Profile Using Continuous Glucose Monitoring System in Glucose Intolerant Patients

NCT ID: NCT04343040

Last Updated: 2022-03-15

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

76 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-09-30

Study Completion Date

2024-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The recent use of a pre-operative carbohydrate loading compared to fasting has been shown to improve the early recovery after surgical procedures by reducing the profound stress response following surgery and allowing a better postoperative blood glucose regulation by lowering insulin resistance. The responsible mechanisms of T2D remission after bariatric surgery are not completely understood and guidelines for the early management of T2D and GI following bariatric surgery are lacking, resulting in highly variable postoperative glucose control. No other study has yet investigated the effect of preoperative carbohydrate loading on glucose control the first days after the bariatric surgery in patients who have poor glycemic control

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Bariatric surgery allows weight loss and obesity related comorbidities remission. In patients with type 2 diabetes (T2D), glucose intolerance (GI) and metabolic syndrome (MS), weight loss surgery improves glucose control more than medications and/or life style intervention. This approach is gaining acceptance even in patients with mild obesity and indications are now rapidly growing. Roux en Y gastric bypass (RYGB) and Sleeve Gastrectomy (SG) the gold standard operations for treating T2D, lower glycemia often very rapidly and sometime profoundly. The responsible mechanisms are not completely understood and guidelines for the early management of T2D and GI following bariatric surgery are lacking, resulting in highly variable postoperative glucose control.

The recent use of a pre-operative carbohydrate loading compared to fasting has been shown to improve the early recovery after surgical procedures by reducing the profound stress response following surgery and allowing a better postoperative blood glucose regulation by lowering insulin resistance.

Metabolic stress and insulin resistance follow major surgery. The resulting post-operative hyperglycaemia is associated with increased morbidity as well as mortality. In non-diabetic patients, avoiding pre-operative fastening substantially reduces post-operative stress and insulin resistance. A pre-operative carbohydrate load improves post-operative glycaemic control, most likely by inducing endogenous insulin release before the onset of surgery. This sets the metabolic state of the patient in a fed rather than a fasted state at the time of surgery. Metabolic reactions to surgical stress are thereby markedly reduced not only resulting in a reduced risk for hyperglycaemia during post-operative nutrition but also retained lean body mass, improved muscle strength and nitrogen economy.

The oral preparation used is a carbohydrate-rich clear beverage containing mainly polymers of carbohydrates to minimize the osmotic load. The drink, in addition to its metabolic effect, improves patient well-being (thirst, hunger, anxiety) pre-operatively. Oral preload is considered the first element in the surgical pathway to reduce patients' stress with the aim of early return to oral diet, mobility and recovery as soon as possible after surgery and had a significant effect on reducing complications and improving wellbeing.

Patients with GI and T2D are at particular risk of impaired glycaemic control peri-operatively. Most of the studies using pre-operative carbohydrate loading were performed on non-diabetic patients. A considerable number of patients going through bariatric surgery suffer from GI or T2D (respectively 30% and 15% in our experience), this patient group has been denied initially for the pre-operative carbohydrate drink because of fear of slow gastric emptying and impaired glycaemic control. We are aware of only one study that evaluated the suitability for diabetic patients to have preload drinks pre-operatively . Gustafsson et al explored the possibility of providing pre-operative carbohydrate loading in patients with mild T2D without neuropathy or delayed gastric emptying (as autonomic neuropathy is a likely cause of delayed gastric function in diabetes). In this study, T2D patients (n=25) showed no signs of hyperglycaemia. However, the wider spectrum of diabetic patients was not evaluated. Can et al. also evaluated the effects of pre-operative pre-loading in patients with or without insulin resistance. This differed from other studies, which had previously excluded those with known insulin resistance. This study included 34 cholecystectomy or thyroidectomy patients showed that the temporal pattern of plasma glucose in patients with insulin resistance who were given preload drinks pre-operatively was similar to that of patients without insulin resistance. These studies suggest that there might be a benefit without risk of hyperglycaemia to give to type-2 diabetic (and GI) patients a preload along with their usual diabetic medication. No other study has yet investigated the effect of preoperative carbohydrate loading on glucose control the first days after the bariatric surgery in patients who have poor glycemic control. Furthermore, most bariatric surgery studies include only late postoperative evaluations of glucose control, such as those made after 7 days or more.

The main hypothesis of this study is that pre-operative carbohydrate loading compared to fasting will optimize the overall pattern of postoperative glucose profile evidenced by Continuous Glucose Monitoring (CGM) with a greater impact in the first few days after surgery on lowering mean glycaemia and glycemic variability in patients with glucose intolerance.

The primary aim is to evaluate the mean of all blood glucose measures of CGM over 24-h period after surgery in patients receiving pre-operative carbohydrate loading in comparison with standard 6h fasting. The mean of all glucose measures over 24- h of CGM (around 288) reflects overall glucose control including fasting and postprandial state. It have been chose to study this early period to minimize any confounding effects of weight loss.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hyperglycaemia (Diabetic) Bariatric Surgery Candidate

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

perioperative glucose intake

glucose intolerant patients with perioperative glucose (carbohydrate supplement (Preload™) intake before Gastric By-Pass or Sleeve Gastrectomy.

Group Type EXPERIMENTAL

carbohydrate supplement (Preload™)

Intervention Type DIETARY_SUPPLEMENT

carbohydrate supplement (Preload™) will be administered 4-hours prior to bariatric surgery (experimental treatment) Preload™ is a neutral-tasting carbohydrate loading drink mix specifically designed for use before elective surgery. Preload is presented in 50g pre-measured sachets which when added to water (400ml) produces a solution with low osmolality.

6 hours of preoperative fasting

glucose intolerant patients receiving 6 hours of preoperative fasting before Gastric By-Pass or Sleeve Gastrectomy.

Group Type SHAM_COMPARATOR

6 hours of preoperative fasting

Intervention Type PROCEDURE

Standard of care. In this group, patients continue the standard of care treatment before surgery with fasting recommended 6 hours before surgery.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

carbohydrate supplement (Preload™)

carbohydrate supplement (Preload™) will be administered 4-hours prior to bariatric surgery (experimental treatment) Preload™ is a neutral-tasting carbohydrate loading drink mix specifically designed for use before elective surgery. Preload is presented in 50g pre-measured sachets which when added to water (400ml) produces a solution with low osmolality.

Intervention Type DIETARY_SUPPLEMENT

6 hours of preoperative fasting

Standard of care. In this group, patients continue the standard of care treatment before surgery with fasting recommended 6 hours before surgery.

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Bariatric surgery planned (RYGB or SG)
* BMI at least 35 kg/m2 with comorbidity that can be improved after surgery(including cardiovascular disease including high blood pressure, obstructive sleep apnea syndrome and other severe respiratory disorders, severe metabolic disorders, particularly type 2 diabetes, disabling osteoarticular disease, steatohepatitis non-alcoholic)
* Glucose Intolerance as defined by the American Diabetes Association (ADA Diabetes Care 2017)
* Negative pregnancy test
* Informed consent
* Patient with social insurance

Exclusion Criteria

* Patients receiving insulin therapy
* Previous bariatric surgery
* Definite symptoms of gastroparesis assessed by Gastroparesis Cardinal Symptoms Index (GCSI)\*. Values of score ≥ 1.90 will be chosen as definite symptoms of gastroparesis.
* Pregnant or breastfeeding woman, persons deprived of their liberty, persons under guardianship or trusteeship
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University Hospital, Lille

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Robert Caiazzo, MD,PhD

Role: PRINCIPAL_INVESTIGATOR

University Hospital, Lille

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Robert Caiazzo, MD,PhD

Role: CONTACT

03 20 44 53 21 ext. +33

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2017-A03320-53

Identifier Type: OTHER

Identifier Source: secondary_id

2017_34

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Mechanisms of Post-Bariatric Hypoglycemia
NCT04428866 ACTIVE_NOT_RECRUITING